IR Banner

Press Releases

Date Title and Summary Additional Format
Nov 29, 2022
Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD
AUSTIN, Texas , Nov. 29, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.  (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on rare endocrine disorders, announced that the Company will host two key opinion leaders in the field of pediatric endocrinology for a discussion of interim data
Nov 22, 2022
Lumos Pharma to Participate in the Piper Sandler 34th Annual Healthcare Conference
AUSTIN, Texas , Nov. 22, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.  (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that the Company will present and host
Nov 14, 2022
Lumos Pharma Reports Third Quarter 2022 Financial Results and Clinical Development Updates
-- Interim Data for Potentially the First Oral Medication for PGHD from Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials Met Expectations with an Encouraging Growth Response of 8.6 cm/yr at six months for the LUM-201 Dose of 1.6 mg/kg/day in the OraGrowtH210 Trial which Supports Advanced Planning
Nov 14, 2022
Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency
- LUM-201, potentially the first oral medication for PGHD, met expectations in an interim analysis of two Phase 2 trials evaluating growth in Pediatric Growth Hormone Deficiency (PGHD) - - Interim results for approximately 50% enrollment (n=41) of OraGrowtH210 Trial demonstrated a mean annualized
Sep 26, 2022
Lumos Pharma to Participate in the Cantor Neurology & Psychiatry Conference
AUSTIN, Texas , Sept. 26, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.  (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that Lumos Pharma management will
Aug 31, 2022
Lumos Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
AUSTIN, Texas , Aug. 31, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.  (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that the Company will present and host
Aug 16, 2022
Lumos Pharma Announces Share Repurchase Program
-- Plan to Repurchase Up to $3 Million of Common Shares -- AUSTIN, Texas , Aug. 16, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (“The Company,” NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth
Aug 9, 2022
Lumos Pharma Reports Second Quarter 2022 Financial Results and Clinical Development Updates
-- Continue to Anticipate Interim Data from Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials in Q4 2022 -- -- Primary Outcome Readouts from Both Trials Anticipated 2H 2023 with Data in up to 24 Patients Anticipated from OraGrowtH212 Trial -- -- Cash Runway into Second Quarter 2024 -- AUSTIN,
Jul 27, 2022
Lumos Pharma to Report Second Quarter 2022 Financial Results and Host Conference Call on August 9, 2022
AUSTIN, Texas , July 27, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, today announced it will report its second quarter 2022 financial results after market close on Tuesday, August 9, 2022 . The company will host a conference call and
Jul 26, 2022
CEO Update: Interview with Lumos Pharma’s Chief Medical Officer, David B. Karpf, M.D.
Lumos Pharma CMO, David B. Karpf, M.D., walks us through his background and perspective on LUM-201. Q: When did you know you wanted to go into medicine – what drove you to that profession? A: My dad was an exceptional doctor, so I knew at age 5 that I wanted to be a physician.
Displaying 1 - 10 of 65